diamond research lab

The Diamond laboratory is focused on the development of novel targeted therapies for triple-negative breast cancer, specifically cell cycle targeting agents and combination immunotherapy.  The lab has a special interest in predictive biomarker development and conducting correlative biological assays for early phase clinical trials.

lab personnel

selected publications

Schreiber AR, Andress M, Diamond JR. Tackling metastatic triple-negative breast cancer with sacituzumab govitecan. Expert Rev Anticancer Ther. 2021 Dec;21(12):1303-1311. doi: 10.1080/14737140.2021.1993065. Epub 2021 Oct 22. PMID: 34651524.

Marín-Jiménez JA, Capasso A, Lewis MS, Bagby SM, Hartman SJ, Shulman J, Navarro NM, Yu H, Rivard CJ, Wang X, Barkow JC, Geng D, Kar A, Yingst A, Tufa DM, Dolan JT, Blatchford PJ, Freed BM, Torres RM, Davila E, Slansky JE, Pelanda R, Eckhardt SG, Messersmith WA, Diamond JR, Lieu CH, Verneris MR, Wang JH, Kiseljak-Vassiliades K, Pitts TM, Lang J. Testing Cancer Immunotherapy in a Human Immune System Mouse Model: Correlating Treatment Responses to Human Chimerism, Therapeutic Variables and Immune Cell Phenotypes. Front Immunol. 2021 Mar 29;12:607282. doi: 10.3389/fimmu.2021.607282. PMID: 33854497.

Kagihara JA, Shagisultanova E, Afghahi A, Diamond JR. Moving Towards Targeted Therapies for Triple-Negative Breast Cancer. Curr Breast Cancer Rep. 2021 Sep;13(3):216-226. doi: 10.1007/s12609-021-00416-0. Epub 2021 May 4. PMID: 34457184.

View All Publications